Arcus Biosciences reported a net loss of $45.1 million for the second quarter of 2020. The company strengthened its balance sheet by raising approximately $348 million in gross proceeds from a public offering and established a 10-year global partnership with Gilead.
Established a 10-year global partnership with Gilead to co-develop and co-commercialize next-generation cancer immunotherapies.
Raised approximately $348 million in gross proceeds from a public offering of Arcus’s common stock.
Presented early clinical activity of etrumadenant (AB928) in late-line metastatic colorectal cancer patients.
Initiated enrollment in ARC-6, a Phase 1b/2 platform trial in metastatic castrate resistant prostate cancer.
Arcus Biosciences anticipates several near-term corporate milestones.
Analyze how earnings announcements historically affect stock price performance